Biosimilars demonstrate comparable drug survival and safety with adalimumab among new users, but patients switching from Humira (the originator product) to biosimilars had a 35% higher discontinuation ...
Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising ...
REDWOOD CITY, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS), today announced that YUSIMRY™ (adalimumab-aqvh) is now available for commercial sale in the United States at a ...
Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
High- and low-concentration interchangeable biosimilar will be available, estimated to save individual patients around $3,500 on average per year Biosimilar price will be about 85% lower than Humira ® ...
The expanded interchangeability now applies to the 40mg prefilled syringe and the 40mg and 80mg autoinjectors, in addition to the 20mg and 80mg prefilled syringes. The Food and Drug Administration ...
Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these ...
Amgen on Thursday settled a patent lawsuit with Abbvie over its biosimilar version of Abbvie’s best-selling arthritis drug Humira, reports Reuters. The settlement will delay the launch of Amgen’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results